Previous 10 | Next 10 |
Recent news releases related news releases and press releases from 06/11/21 03:01:00 on US and Canada Markets.
- Exploratory biomarker analyses suggest possible cardiac disease improvements and renal response - Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced new Phase 2 safety and tolerability data for CAEL-101, a potentially first-in-class amyl...
Robust decreases in serum IgM at low- and mid-doses suggest best-in-class potential for mavorixafor plus ibrutinib therapy in double-mutation Waldenström’s patients; meaningful increases in hemoglobin levels suggest reduction in cancer burden in bone marrow ...
Results showed treatment with Reblozyl plus best supportive care improved anemia in 77% of patients compared to placebo Reblozyl was generally well tolerated and improvements in hemoglobin correlated with improved patient-reported outcomes over a continuous 12-we...
The Phase 3 ALPINE trial met the primary endpoint at interim analysis, with BRUKINSA showing superiority in investigator-assessed overall response rate versus ibrutinib Early progression-free survival and overall survival data are supportive of findings in response rate ...
– Study Met Primary Endpoint; Treatment with Mitapivat Induced Hemoglobin Increase of ≥1.0 g/dL in 16 of 20 (80%) Patients During Weeks 4-12 – – Mitapivat Safety Profile Consistent with Previously Published Studies – – Agios to H...
– Company Expects to File for Regulatory Approval for Mitapivat for the Treatment of Adults with PK Deficiency in the U.S. This Quarter and in the EU in Mid-2021 – – Agios to Host Investor Webcast Today at 7:30 a.m. ET – CAMBRIDGE, Mas...
Final data from 93-patient Phase 2a clinical trial show lower annualized rate of vaso-occlusive crises (VOCs) and longer time to first VOC on IMR-687 Interim open-label extension clinical trial data through eight months show increased HbF response and continuation of lower VOC r...
Momelotinib Oral Presentation at European Hematology Association Demonstrates Association Between Transfusion Independence and Improved Overall Survival Canada NewsWire —Additional poster presentation highlights improved transfusion independence of momelotinib i...
Results showed treatment with Reblozyl plus best supportive care improved anemia in 77% of patients compared to placebo Reblozyl was generally well tolerated and improvements in hemoglobin correlated with improved patient-reported outcomes over a continuous 12-we...
Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation Two Real-world Data Studies Demonstrated Sustained Improvements in Hemoglobin with Oxbryta Consistent with Results from the Phase 3 HOPE Study SOUTH SAN FRANCISCO, Calif., June 11, 2021 (GLOBE NEWSWIRE)...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
100.0%Change Percent:
Wuxi Biologics Cayman Inc Company Name:
WXIBF Stock Symbol:
OTCMKTS Market: